Grant GrossMendelsohn LLC Has $2.18 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Grant GrossMendelsohn LLC trimmed its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,299 shares of the company's stock after selling 14,331 shares during the quarter. Tarsus Pharmaceuticals accounts for 1.1% of Grant GrossMendelsohn LLC's portfolio, making the stock its 27th largest holding. Grant GrossMendelsohn LLC owned approximately 0.10% of Tarsus Pharmaceuticals worth $2,176,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Canada Pension Plan Investment Board acquired a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth about $114,000. FMR LLC increased its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after buying an additional 3,537 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Tarsus Pharmaceuticals by 87.5% in the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock valued at $238,000 after acquiring an additional 3,379 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 64.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company's stock valued at $241,000 after acquiring an additional 2,879 shares during the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter worth approximately $202,000. 90.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on TARS shares. The Goldman Sachs Group upped their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research report on Friday, November 15th. Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $54.20.

Tarsus Pharmaceuticals Trading Down 0.9 %

TARS traded down $0.40 during mid-day trading on Friday, hitting $46.52. The stock had a trading volume of 357,669 shares, compared to its average volume of 576,498. The stock's fifty day simple moving average is $50.95 and its 200-day simple moving average is $38.27. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -12.21 and a beta of 1.02. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.14. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.